SCHEMBL19664253

SCHEMBL19664253

CC(C)C(=O)Nc1ccc2oc(-c3c(Cl)cccc3Cl)nc2c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.68
ALDH1A1 P00352 4/20 0.68
RAB9A P51151 4/20 0.68
SMN1; SMN2 Q16637 4/20 0.68
KDM4E B2RXH2 3/20 0.68
HSD17B10 Q99714 3/20 0.65
HPGD P15428 2/20 0.65
TP53 P04637 1/20 0.65
GAA P10253 1/20 0.65
THRB P10828 1/20 0.65
TSHR P16473 1/20 0.65
NPSR1 Q6W5P4 1/20 0.65
UTRN P46939 1/20 0.64
CASP3 P42574 1/20 0.64
SENP7 Q9BQF6 1/20 0.64
USP2 O75604 2/20 0.62
LMNA P02545 1/20 0.62
MAPK1 P28482 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
POLB P06746 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2242151 0.92 SMN1; SMN2 (0.71) NPC1ALDH1A1RAB9ASMN1; SMN2KDM4E
SCHEMBL2240335 0.88 NPC1 (0.70) NPC1ALDH1A1RAB9ASMN1; SMN2KDM4E
SCHEMBL2246997 0.87 NPC1 (0.73) NPC1ALDH1A1RAB9ASMN1; SMN2KDM4E
SCHEMBL2242964 0.86 SMN1; SMN2 (0.74) NPC1ALDH1A1RAB9ASMN1; SMN2KDM4E
SCHEMBL2245441 0.85 CASP3 (0.75) NPC1ALDH1A1RAB9ASMN1; SMN2KDM4E
SCHEMBL2243066 0.84 CASP3 (0.74) NPC1ALDH1A1RAB9ASMN1; SMN2KDM4E
SCHEMBL2247011 0.83 NPC1 (0.74) NPC1ALDH1A1RAB9ASMN1; SMN2KDM4E
SCHEMBL2242010 0.83 NPC1 (0.77) NPC1ALDH1A1RAB9ASMN1; SMN2KDM4E
SCHEMBL2243398 0.82 CASP3 (0.87) NPC1ALDH1A1RAB9ASMN1; SMN2KDM4E
SCHEMBL2242920 0.82 SMN1; SMN2 (0.80) NPC1ALDH1A1RAB9ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3251694-A1 DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Summit (Oxford) Limited (GB) 2017-12-06 EP disclosed